The aims of our study were to: (1) analyze both clinical and neuroimaging (structural and functional) characteristics of patients with focal epilepsy (FE) + GAD ab at epilepsy onset and during follow-up, (2) compare these characteristics with those of a control group of clinically similar patients without antibodies, and (3) describe the most affected cerebral areas in structural and functional imaging. This evidence concerns the gene GAD1 and focal epilepsy.